JP2021522802A5 - - Google Patents

Info

Publication number
JP2021522802A5
JP2021522802A5 JP2020561923A JP2020561923A JP2021522802A5 JP 2021522802 A5 JP2021522802 A5 JP 2021522802A5 JP 2020561923 A JP2020561923 A JP 2020561923A JP 2020561923 A JP2020561923 A JP 2020561923A JP 2021522802 A5 JP2021522802 A5 JP 2021522802A5
Authority
JP
Japan
Prior art keywords
composition according
treatment period
compound
hcv
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020561923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522802A (ja
JP7279081B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/031044 external-priority patent/WO2019217369A1/en
Publication of JP2021522802A publication Critical patent/JP2021522802A/ja
Publication of JP2021522802A5 publication Critical patent/JP2021522802A5/ja
Application granted granted Critical
Publication of JP7279081B2 publication Critical patent/JP7279081B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561923A 2018-05-08 2019-05-07 Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法 Active JP7279081B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862668467P 2018-05-08 2018-05-08
US62/668,467 2018-05-08
PCT/US2019/031044 WO2019217369A1 (en) 2018-05-08 2019-05-07 Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect

Publications (3)

Publication Number Publication Date
JP2021522802A JP2021522802A (ja) 2021-09-02
JP2021522802A5 true JP2021522802A5 (enExample) 2022-05-13
JP7279081B2 JP7279081B2 (ja) 2023-05-22

Family

ID=66625315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561923A Active JP7279081B2 (ja) 2018-05-08 2019-05-07 Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法

Country Status (7)

Country Link
US (1) US12005120B2 (enExample)
EP (1) EP3790972A1 (enExample)
JP (1) JP7279081B2 (enExample)
CN (1) CN112400020B (enExample)
CA (1) CA3099698A1 (enExample)
TW (1) TWI854980B (enExample)
WO (1) WO2019217369A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113718024A (zh) * 2020-05-26 2021-11-30 深圳市血液中心 血浆miRNA标志物及其应用
JP2024535445A (ja) * 2021-10-08 2024-09-30 レグルス セラピューティクス インコーポレイテッド オフターゲット効果を回避するための方法及び組成物
AU2023238507A1 (en) * 2022-03-25 2024-10-31 Hansoh Bio Llc Bicyclic heterocycles and their ligands for targeted delivery of therapeutic agents

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10503364A (ja) 1994-05-10 1998-03-31 ザ ジェネラル ホスピタル コーポレーション Ｃ型肝炎ウイルスのアンチセンス阻害
TW520293B (en) 1995-11-22 2003-02-11 Univ Johns Hopkins Med Delivery system to enhance cellular uptake of biomolecules
US6300319B1 (en) 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
AU7406700A (en) 1999-10-04 2001-05-10 Exiqon A/S Design of high affinity rnase h recruiting oligonucleotide
WO2001048190A2 (en) 1999-12-23 2001-07-05 Exiqon A/S Therapeutic uses of lna-modified oligonucleotides
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
CN100406065C (zh) 2000-12-01 2008-07-30 细胞工厂治疗公司 糖基化/半乳糖基化肽、双官能接头和核苷酸单体/多聚体的缀合物以及相关的组合物和使用方法
CN1344803A (zh) 2001-09-27 2002-04-17 吴昌 核酸靶分子选择及扩增方法
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
JP4989225B2 (ja) 2003-09-25 2012-08-01 コーリー ファーマシューティカル グループ，インコーポレイテッド 核酸親油性接合体
ES2344566T3 (es) 2003-12-23 2010-08-31 Santaris Pharma A/S Compuestos oligomericos para la modulacion de bcl-2.
AU2005325262B2 (en) 2004-04-27 2011-08-11 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
PT1747023E (pt) 2004-05-04 2011-04-11 Univ Leland Stanford Junior Métodos e composições para reduzir quantidades de genoma viral numa célula alvo
EP1913011B1 (en) 2004-08-04 2016-11-02 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
WO2006031461A2 (en) 2004-09-09 2006-03-23 Isis Pharmaceuticals, Inc. Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
US20070099196A1 (en) 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
US20120122801A1 (en) 2005-01-05 2012-05-17 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
US20060148740A1 (en) 2005-01-05 2006-07-06 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
EP1841867A1 (en) 2005-01-24 2007-10-10 Avaris AB COMPLEX CONTAINING SiRNA, ShRNA OR ANTISENSE MOLECULE AND FUNCTIONAL ENTITY, FOR IMPROVED SPECIFICITY AND DELIVERY
AU2006279906B2 (en) 2005-08-10 2012-05-10 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007027894A2 (en) 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
ATE494372T1 (de) 2005-08-29 2011-01-15 Regulus Therapeutics Inc Verfahren für mir-122a-modulation
EP2388328A1 (en) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
EA201100811A1 (ru) 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
CA3042781C (en) 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
DK2152879T3 (da) 2007-05-01 2013-02-18 Santaris Pharma As RNA antagonistforbindelser til modulering af beta-catenin
DK2205737T3 (da) 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
NZ585327A (en) 2007-11-26 2012-10-26 Santaris Pharma As Lna antagonists targeting the androgen receptor
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
WO2009091972A2 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010076248A1 (en) 2008-12-31 2010-07-08 Santaris Pharma A/S Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
US9034837B2 (en) 2009-04-24 2015-05-19 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
MA33488B1 (fr) 2009-06-08 2012-08-01 Miragen Therapeutics Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
ES2651308T3 (es) 2009-10-16 2018-01-25 Glaxo Group Limited Inhibidores antisentido de HBV
PH12012501596A1 (en) 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2011130458A2 (en) 2010-04-13 2011-10-20 John Rossi Rna aptamers against baff-r as cell-type specific delivery agents and methods for their use
WO2012007477A1 (en) 2010-07-12 2012-01-19 Santaris Pharma A/S Anti hcv oligomers
US9290760B2 (en) 2010-09-15 2016-03-22 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
RU2013117288A (ru) 2010-12-17 2015-01-27 Эрроухэд Рисерч Корпорейшн СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
RU2582235C2 (ru) 2010-12-29 2016-04-20 Ф.Хоффманн-Ля Рош Аг Низкомолекулярные конъюгаты для внутриклеточной доставки нуклеиновых кислот
MX393138B (es) 2011-04-25 2025-03-24 Sanofi Sa Compuestos de microarn y metodos para modular la actividad de mir-21.
US20140248611A1 (en) 2011-06-16 2014-09-04 Nippon Steel & Sumikin Eco-Tech Corporation Nucleic acid probe for assaying nucleic acids
WO2012175733A1 (en) 2011-06-23 2012-12-27 Santaris Pharma A/S Hcv combination therapy
KR20140058536A (ko) 2011-06-30 2014-05-14 스텔라 에이피에스 Hcv 조합 치료
EP2726610A1 (en) 2011-06-30 2014-05-07 Stella ApS Hcv combination therapy
US10023861B2 (en) * 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
WO2013068348A1 (en) 2011-11-07 2013-05-16 Santaris Pharma A/S Lna oligomers for improvement in hepatic function
EP2776590B1 (en) 2011-11-07 2016-10-26 Roche Innovation Center Copenhagen A/S Prognostic method for checking efficacy of micro rna-122 inhibitors in hcv+ patients
EP2864482A4 (en) 2012-06-21 2016-02-10 Miragen Therapeutics Inc OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
CN104955950B (zh) 2012-09-26 2019-04-26 米尔克斯治疗学公司 具有改善的脱靶特征谱的寡核苷酸
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
CA2893801A1 (en) 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
WO2014118272A1 (en) * 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
EP2992096B1 (en) 2013-05-01 2021-03-03 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
JP2016518842A (ja) * 2013-05-01 2016-06-30 レグルス セラピューティクス インコーポレイテッド マイクロＲＮＡ化合物およびｍｉＲ−１２２をモジュレートする方法

Similar Documents

Publication Publication Date Title
Gentile et al. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir
JP2008518943A5 (enExample)
JP2010503396A5 (enExample)
JP2021521118A5 (enExample)
AR079555A1 (es) Metodos de tratamiento de la infeccion de virus de hepatitis b (hbv) y virus de hepatitis c (hcv)
Bourlière et al. Sofosbuvir as backbone of interferon free treatments
CN108712905B (zh) 抗肝肿瘤病毒剂
WO2010031832A9 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
JP2016518842A5 (enExample)
TW200815384A (en) Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
KR20120139699A (ko) Ｃ형 간염 바이러스 감염의 치료 요법
JP2013540112A (ja) Ｈｃｖ感染を治療するための併用療法
JP2011522862A (ja) テラプレビル（Ｔｅｌａｐｒｅｖｉｒ）投薬養生法
US10471048B2 (en) Thienopyridine derivative for the treatment of hepatitis C infections
US20130028865A1 (en) Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside
WO2014033668A2 (en) Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir
JP2021523129A5 (enExample)
Garg et al. Management of HCV infection: current issues and future options
Amblard et al. Nucleoside Antiviral Agents for HCV: what's Left to Do?
Reviriego Daclatasvir dihydrochloride
US10201541B1 (en) Compositions and methods for treating HCV
US20130273003A1 (en) Therapies for Treating Hepatitis C Virus Infection
JP2017514834A (ja) Ｈｃｖ感染症を治療するための組合せ療法
Kaur et al. Emerging therapies in pipeline for chronic hepatitis C
HK1131339A1 (en) Prophylactic or therapeutic agent for viral disease